www.fdanews.com/articles/134030-cancer-drug-developer-endocyte-drops-price-for-initial-offering

Cancer Drug Developer Endocyte Drops Price for Initial Offering

February 4, 2011

Endocyte Inc., a developer of drugs for ovarian and lung tumors, cut the price for its initial public offering by as much as 53 percent.
Bloomberg